If artificial intelligence is the principal investment theme preoccupying public markets, with “frontier lab” Anthropic having filed for an IPO amid fears of a bubble, AI looms even larger over private markets. AI-related businesses captured 83% of all US venture capital investment in the third quarter—the most on record. AI unicorns are also commanding ever higher valuations, as detailed in the Unicorn Market Monitor: Q3 2026 from Morningstar Indexes and the Global Unicorn Tracker Q3 2026 from PitchBook.
The Morningstar PitchBook GenAI 20 Index, which tracks pure plays across the public-private spectrum, gained 25.8% in the third quarter and an astounding 175.4% through the first nine months of 2026. That’s well ahead of the 13% gain posted by Morningstar’s global equities benchmark through the third quarter. The GenAI index, which includes the likes of Anthropic and OpenAI, has also outpaced the impressive gains for the comprehensive Morningstar PitchBook Global Unicorn Index. Private market investment in AI extends beyond foundation models into infrastructure and applications.
AI Has Powered Private Market Valuation to Higher Heights in 2026
Source: Morningstar Direct. Data as of 09/30/2026. GenAI 20 values private constituents based on their last funding round, while Global Unicorns uses an estimation model that considers funding rounds as well as public and private market comparables.
The Global Unicorn Index, which currently includes nearly 1,500 private companies valued at more than $1 billion, added another 72 constituents in the third quarter. That’s a slower rate of growth than witnessed in the first two quarters of 2026. The index advanced only 1.1% in the third quarter, a marked slowdown from its 43% second quarter return. Still, the funding environment remains robust. Strong 2026 returns for the Global Unicorn Index owes not just to Anthropic, but also companies across geography, such as ByteDance, Anduril, and Mistral AI, which are commanding higher valuations. Outside of AI, the healthcare vertical is another area of private market strength, with the Morningstar PitchBook Global BioPharma Unicorn Index rising more than 14% in the third quarter.
Anthropic’s IPO showcases a key exit route for unicorns, acquisitions another. In the third quarter, 15 constituents of the Global Unicorn Index were acquired, while seven conducted IPOs. The fact that some of those public offerings were priced below their latest private valuations demonstrates a risk that investors must consider.
©2026 Morningstar. All Rights Reserved. The information, data, analyses and opinions contained herein (1) include the proprietary information of Morningstar, (2) may not be copied or redistributed, (3) do not constitute investment advice offered by Morningstar, (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (5) are not warranted to be correct, complete or accurate. Morningstar has not given its consent to be deemed an "expert" under the federal Securities Act of 1933. Except as otherwise required by law, Morningstar is not responsible for any trading decisions, damages or other losses resulting from, or related to, this information, data, analyses or opinions or their use. References to specific securities or other investment options should not be considered an offer (as defined by the Securities and Exchange Act) to purchase or sell that specific investment. Past performance does not guarantee future results. Before making any investment decision, consider if the investment is suitable for you by referencing your own financial position, investment objectives, and risk profile. Always consult with your financial advisor before investing.
Indexes are unmanaged and not available for direct investment.
Morningstar indexes are created and maintained by Morningstar, Inc. Morningstar® is a registered trademark of Morningstar, Inc.
